Arthralgia
Conditions
Keywords
Bevacizumab
Brief summary
Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers. The principal end-point is the frequency of arthralgia after 6 months of treatment with Bevacizumab.
Interventions
None listed
Sponsors
University Hospital, Lille
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy * Male or female (aged ≥18 years old) * Performance Status (PS) between 0 and 2 * Expected life\> 3 months * Ability to answer a self-questionnaire * Obtaining the non-opposition of patient participation
Exclusion criteria
* Pregnant or lactating woman * Rapid evolution of neoplastic pathology * Major cognitive disorders that do not allow filling of the self-questionnaire * Impossibility to submit to medical monitoring for social, psychological or geographical reasons * Patients under guardianship or curatorship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of arthralgia | At 6 months | Frequency of joint manifestations of any grade according to the CTCAE (Common Terminology Criteria for Adverse Events) scale version 4.0 observed between the start of bevacizumab treatment and 6 months of treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| correlation between global cancer response and occurrence of arthralgia | baseline, at 3 months, at 6 months | — |
| auto questionnaire specific to the study | Baseline at 3 months, at 6 months | 16 questions concerning the location, intensity, management of joint pain |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORMarie-Hélène Viellard, MD
University Hospital, Lille
Outcome results
None listed